| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stroke | 27 | 2024 | 310 | 5.360 |
Why?
|
| Tissue Plasminogen Activator | 8 | 2023 | 24 | 2.450 |
Why?
|
| Ischemic Attack, Transient | 13 | 2022 | 27 | 2.270 |
Why?
|
| Hypertension | 7 | 2025 | 469 | 1.710 |
Why?
|
| Carotid Stenosis | 4 | 2022 | 8 | 1.520 |
Why?
|
| Fibrinolytic Agents | 7 | 2023 | 44 | 1.410 |
Why?
|
| Brain Ischemia | 8 | 2023 | 37 | 1.260 |
Why?
|
| Humans | 52 | 2025 | 17376 | 1.020 |
Why?
|
| Telemedicine | 2 | 2020 | 182 | 0.990 |
Why?
|
| Thrombolytic Therapy | 4 | 2017 | 19 | 0.940 |
Why?
|
| Female | 34 | 2025 | 12444 | 0.840 |
Why?
|
| Diabetes, Gestational | 6 | 2015 | 312 | 0.830 |
Why?
|
| Patient Readmission | 1 | 2025 | 165 | 0.820 |
Why?
|
| Middle Aged | 23 | 2025 | 7885 | 0.790 |
Why?
|
| Aged, 80 and over | 11 | 2025 | 1942 | 0.780 |
Why?
|
| Dietary Approaches To Stop Hypertension | 1 | 2022 | 4 | 0.780 |
Why?
|
| Mentoring | 1 | 2022 | 26 | 0.750 |
Why?
|
| Aged | 19 | 2025 | 6129 | 0.750 |
Why?
|
| Embolization, Therapeutic | 1 | 2020 | 5 | 0.690 |
Why?
|
| Endovascular Procedures | 1 | 2020 | 7 | 0.690 |
Why?
|
| Hospitals, Community | 1 | 2020 | 22 | 0.680 |
Why?
|
| Male | 21 | 2025 | 9843 | 0.680 |
Why?
|
| Breast Feeding | 3 | 2015 | 113 | 0.670 |
Why?
|
| Cardiovascular Diseases | 6 | 2024 | 533 | 0.670 |
Why?
|
| Hypertension, Pregnancy-Induced | 3 | 2025 | 39 | 0.650 |
Why?
|
| Hospital Mortality | 1 | 2020 | 135 | 0.640 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 50 | 0.640 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 57 | 0.640 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2020 | 203 | 0.610 |
Why?
|
| Pandemics | 1 | 2020 | 285 | 0.580 |
Why?
|
| Risk Factors | 15 | 2025 | 3255 | 0.540 |
Why?
|
| Cohort Studies | 12 | 2025 | 2526 | 0.530 |
Why?
|
| Prospective Studies | 10 | 2025 | 1229 | 0.530 |
Why?
|
| Cerebral Angiography | 3 | 2011 | 5 | 0.520 |
Why?
|
| Lactation | 4 | 2014 | 34 | 0.500 |
Why?
|
| Breast Neoplasms | 4 | 2024 | 977 | 0.490 |
Why?
|
| Pre-Eclampsia | 3 | 2025 | 40 | 0.480 |
Why?
|
| Pregnancy | 11 | 2025 | 1466 | 0.480 |
Why?
|
| Antihypertensive Agents | 1 | 2016 | 155 | 0.470 |
Why?
|
| California | 10 | 2025 | 2317 | 0.470 |
Why?
|
| Hospitalization | 3 | 2021 | 805 | 0.460 |
Why?
|
| Thrombectomy | 2 | 2011 | 2 | 0.450 |
Why?
|
| Endarterectomy, Carotid | 3 | 2022 | 5 | 0.450 |
Why?
|
| Blood Pressure | 3 | 2025 | 275 | 0.430 |
Why?
|
| Life Style | 4 | 2022 | 316 | 0.390 |
Why?
|
| Adult | 14 | 2025 | 7529 | 0.380 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2017 | 537 | 0.370 |
Why?
|
| Epidemiologic Studies | 1 | 2011 | 29 | 0.360 |
Why?
|
| Angioplasty | 1 | 2011 | 1 | 0.360 |
Why?
|
| Severity of Illness Index | 2 | 2025 | 439 | 0.360 |
Why?
|
| United States | 12 | 2025 | 3891 | 0.350 |
Why?
|
| Treatment Outcome | 5 | 2023 | 1170 | 0.340 |
Why?
|
| Myocardial Infarction | 3 | 2021 | 225 | 0.320 |
Why?
|
| Early Diagnosis | 1 | 2009 | 36 | 0.310 |
Why?
|
| Heart Failure | 3 | 2024 | 404 | 0.310 |
Why?
|
| Incidence | 5 | 2022 | 1266 | 0.310 |
Why?
|
| African Continental Ancestry Group | 2 | 2016 | 144 | 0.300 |
Why?
|
| Lipids | 2 | 2014 | 69 | 0.290 |
Why?
|
| Intracranial Arteriosclerosis | 1 | 2008 | 1 | 0.290 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2015 | 666 | 0.290 |
Why?
|
| Retrospective Studies | 6 | 2025 | 2428 | 0.290 |
Why?
|
| European Continental Ancestry Group | 2 | 2016 | 480 | 0.270 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2021 | 380 | 0.270 |
Why?
|
| Metabolic Syndrome | 2 | 2014 | 65 | 0.260 |
Why?
|
| Primary Prevention | 2 | 2024 | 63 | 0.260 |
Why?
|
| Platelet Aggregation Inhibitors | 3 | 2013 | 24 | 0.250 |
Why?
|
| Asymptomatic Diseases | 2 | 2022 | 26 | 0.240 |
Why?
|
| Blood Pressure Determination | 3 | 2025 | 52 | 0.240 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2025 | 26 | 0.240 |
Why?
|
| Emergency Treatment | 1 | 2005 | 7 | 0.240 |
Why?
|
| Patient Discharge | 2 | 2020 | 154 | 0.230 |
Why?
|
| Asian Americans | 1 | 2005 | 164 | 0.230 |
Why?
|
| American Heart Association | 1 | 2024 | 48 | 0.220 |
Why?
|
| Angioedema | 1 | 2023 | 6 | 0.220 |
Why?
|
| Physicians, Family | 1 | 2003 | 37 | 0.210 |
Why?
|
| Ticlopidine | 1 | 2013 | 16 | 0.210 |
Why?
|
| Carotid Artery, Internal | 1 | 2003 | 1 | 0.210 |
Why?
|
| Sex Factors | 3 | 2011 | 607 | 0.200 |
Why?
|
| Insulin Resistance | 2 | 2014 | 128 | 0.200 |
Why?
|
| Cancer Survivors | 1 | 2024 | 101 | 0.200 |
Why?
|
| Medication Adherence | 1 | 2024 | 239 | 0.190 |
Why?
|
| Adipose Tissue | 2 | 2015 | 65 | 0.180 |
Why?
|
| Glucose Intolerance | 1 | 2011 | 43 | 0.180 |
Why?
|
| Markov Chains | 3 | 2011 | 22 | 0.170 |
Why?
|
| Risk Assessment | 2 | 2020 | 1079 | 0.170 |
Why?
|
| Culturally Competent Care | 1 | 2020 | 11 | 0.170 |
Why?
|
| Ambulances | 1 | 2020 | 2 | 0.170 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2020 | 7 | 0.170 |
Why?
|
| Cerebral Infarction | 1 | 2020 | 6 | 0.170 |
Why?
|
| Angiography | 1 | 2020 | 12 | 0.170 |
Why?
|
| Racism | 1 | 2020 | 20 | 0.170 |
Why?
|
| Betacoronavirus | 1 | 2020 | 37 | 0.170 |
Why?
|
| Cost-Benefit Analysis | 3 | 2011 | 226 | 0.160 |
Why?
|
| Length of Stay | 1 | 2020 | 171 | 0.160 |
Why?
|
| Pregnancy in Adolescence | 1 | 2009 | 5 | 0.160 |
Why?
|
| Acute Disease | 2 | 2011 | 144 | 0.150 |
Why?
|
| Body Height | 1 | 2009 | 60 | 0.150 |
Why?
|
| Health Status Disparities | 1 | 2020 | 148 | 0.150 |
Why?
|
| Decision Trees | 2 | 2011 | 18 | 0.150 |
Why?
|
| Prognosis | 3 | 2016 | 604 | 0.150 |
Why?
|
| Atrial Fibrillation | 1 | 2020 | 172 | 0.150 |
Why?
|
| Comorbidity | 1 | 2020 | 564 | 0.150 |
Why?
|
| Registries | 3 | 2011 | 460 | 0.150 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 205 | 0.150 |
Why?
|
| Time Factors | 3 | 2017 | 1044 | 0.150 |
Why?
|
| Adolescent | 6 | 2016 | 3533 | 0.140 |
Why?
|
| Young Adult | 6 | 2016 | 2473 | 0.130 |
Why?
|
| Longitudinal Studies | 4 | 2015 | 677 | 0.130 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2024 | 165 | 0.130 |
Why?
|
| Infant | 4 | 2016 | 1162 | 0.130 |
Why?
|
| Socioeconomic Factors | 2 | 2016 | 609 | 0.130 |
Why?
|
| Diabetes Mellitus | 1 | 2020 | 455 | 0.130 |
Why?
|
| Age Factors | 2 | 2011 | 884 | 0.130 |
Why?
|
| Parity | 3 | 2011 | 57 | 0.130 |
Why?
|
| Infant Formula | 1 | 2015 | 9 | 0.120 |
Why?
|
| Outcome Assessment (Health Care) | 1 | 2016 | 216 | 0.120 |
Why?
|
| Obesity | 2 | 2015 | 814 | 0.120 |
Why?
|
| Secondary Prevention | 3 | 2020 | 48 | 0.120 |
Why?
|
| Child Development | 1 | 2015 | 53 | 0.120 |
Why?
|
| Recombinant Proteins | 2 | 2012 | 16 | 0.110 |
Why?
|
| Prevalence | 2 | 2011 | 839 | 0.110 |
Why?
|
| Child | 4 | 2016 | 2382 | 0.110 |
Why?
|
| Quality of Health Care | 2 | 2020 | 279 | 0.110 |
Why?
|
| Leptin | 1 | 2014 | 26 | 0.110 |
Why?
|
| Adiponectin | 1 | 2014 | 21 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 2 | 2007 | 311 | 0.110 |
Why?
|
| Sensitivity and Specificity | 2 | 2009 | 300 | 0.100 |
Why?
|
| Prediabetic State | 1 | 2014 | 52 | 0.100 |
Why?
|
| Infant, Newborn | 3 | 2015 | 805 | 0.100 |
Why?
|
| Multivariate Analysis | 3 | 2011 | 538 | 0.100 |
Why?
|
| Intracranial Thrombosis | 1 | 2012 | 1 | 0.100 |
Why?
|
| Emergency Service, Hospital | 2 | 2005 | 381 | 0.090 |
Why?
|
| Central Nervous System Stimulants | 1 | 2011 | 26 | 0.090 |
Why?
|
| Societies, Medical | 1 | 2012 | 71 | 0.090 |
Why?
|
| Inpatients | 1 | 2012 | 79 | 0.090 |
Why?
|
| Infusions, Intravenous | 1 | 2011 | 9 | 0.090 |
Why?
|
| Models, Econometric | 1 | 2011 | 10 | 0.090 |
Why?
|
| Alcohol Drinking | 2 | 2011 | 355 | 0.090 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2011 | 64 | 0.090 |
Why?
|
| Gravidity | 2 | 2011 | 5 | 0.090 |
Why?
|
| Evidence-Based Medicine | 1 | 2012 | 171 | 0.090 |
Why?
|
| Social Class | 1 | 2011 | 117 | 0.090 |
Why?
|
| Proportional Hazards Models | 2 | 2022 | 702 | 0.090 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 120 | 0.080 |
Why?
|
| Insulin | 2 | 2011 | 190 | 0.080 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2020 | 366 | 0.080 |
Why?
|
| Blood Glucose | 2 | 2011 | 315 | 0.080 |
Why?
|
| Drug Therapy, Combination | 2 | 2013 | 107 | 0.070 |
Why?
|
| Aspirin | 2 | 2013 | 63 | 0.070 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2008 | 1 | 0.070 |
Why?
|
| Reference Standards | 1 | 2008 | 15 | 0.070 |
Why?
|
| Ethnic Groups | 1 | 2011 | 456 | 0.070 |
Why?
|
| Child, Preschool | 2 | 2016 | 1375 | 0.070 |
Why?
|
| Anthropometry | 2 | 2015 | 60 | 0.070 |
Why?
|
| Waist Circumference | 2 | 2015 | 33 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2011 | 1155 | 0.070 |
Why?
|
| Recurrence | 1 | 2007 | 165 | 0.070 |
Why?
|
| Research Design | 2 | 2015 | 343 | 0.070 |
Why?
|
| China | 3 | 2011 | 132 | 0.060 |
Why?
|
| Body Weight | 2 | 2015 | 203 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2010 | 1287 | 0.060 |
Why?
|
| Pacific Islands | 1 | 2005 | 6 | 0.060 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2005 | 37 | 0.060 |
Why?
|
| Academic Medical Centers | 1 | 2005 | 24 | 0.060 |
Why?
|
| Cultural Diversity | 1 | 2005 | 17 | 0.060 |
Why?
|
| Confidence Intervals | 1 | 2005 | 231 | 0.060 |
Why?
|
| Survival Analysis | 1 | 2005 | 203 | 0.060 |
Why?
|
| Surveys and Questionnaires | 2 | 2015 | 1287 | 0.060 |
Why?
|
| Cardiovascular Agents | 1 | 2024 | 22 | 0.060 |
Why?
|
| Models, Statistical | 1 | 2005 | 173 | 0.060 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2024 | 31 | 0.050 |
Why?
|
| Intracranial Hemorrhages | 1 | 2023 | 16 | 0.050 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 56 | 0.050 |
Why?
|
| Clinical Competence | 1 | 2003 | 93 | 0.050 |
Why?
|
| Catheterization, Peripheral | 1 | 2003 | 2 | 0.050 |
Why?
|
| Double-Blind Method | 1 | 2013 | 142 | 0.050 |
Why?
|
| Hemorrhage | 1 | 2013 | 62 | 0.050 |
Why?
|
| Aromatase Inhibitors | 1 | 2023 | 33 | 0.050 |
Why?
|
| Tamoxifen | 1 | 2023 | 56 | 0.050 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2023 | 65 | 0.050 |
Why?
|
| Mass Screening | 1 | 2008 | 671 | 0.050 |
Why?
|
| Trastuzumab | 1 | 2022 | 19 | 0.050 |
Why?
|
| Anthracyclines | 1 | 2022 | 14 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2025 | 405 | 0.050 |
Why?
|
| Infant Food | 1 | 2011 | 7 | 0.050 |
Why?
|
| Bottle Feeding | 1 | 2011 | 7 | 0.050 |
Why?
|
| Contraception | 1 | 2011 | 24 | 0.050 |
Why?
|
| Diet | 1 | 2024 | 356 | 0.050 |
Why?
|
| Glucose Tolerance Test | 1 | 2011 | 107 | 0.050 |
Why?
|
| Emergency Medical Services | 1 | 2021 | 48 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2012 | 342 | 0.040 |
Why?
|
| Diet Therapy | 1 | 2020 | 9 | 0.040 |
Why?
|
| Prejudice | 1 | 2020 | 22 | 0.040 |
Why?
|
| Self-Management | 1 | 2020 | 25 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 18 | 0.040 |
Why?
|
| Risk | 2 | 2011 | 498 | 0.040 |
Why?
|
| Health Education | 1 | 2020 | 82 | 0.040 |
Why?
|
| Social Determinants of Health | 1 | 2020 | 37 | 0.040 |
Why?
|
| Risk Reduction Behavior | 1 | 2020 | 104 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2009 | 81 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2009 | 140 | 0.040 |
Why?
|
| Educational Status | 1 | 2009 | 179 | 0.040 |
Why?
|
| Pregnancy Complications | 1 | 2011 | 197 | 0.040 |
Why?
|
| Probability | 1 | 2009 | 72 | 0.040 |
Why?
|
| Body Composition | 1 | 2009 | 91 | 0.040 |
Why?
|
| Coronary Disease | 1 | 2009 | 146 | 0.040 |
Why?
|
| Linear Models | 1 | 2009 | 210 | 0.040 |
Why?
|
| Hispanic Americans | 1 | 2020 | 378 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 274 | 0.040 |
Why?
|
| Continental Population Groups | 1 | 2009 | 289 | 0.040 |
Why?
|
| African Americans | 1 | 2020 | 443 | 0.040 |
Why?
|
| Goals | 1 | 2016 | 28 | 0.030 |
Why?
|
| Heart Diseases | 1 | 2016 | 71 | 0.030 |
Why?
|
| Skinfold Thickness | 1 | 2015 | 17 | 0.030 |
Why?
|
| Exercise | 1 | 2020 | 513 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2009 | 937 | 0.030 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2014 | 12 | 0.030 |
Why?
|
| Lipoproteins | 1 | 2014 | 13 | 0.030 |
Why?
|
| Postpartum Period | 1 | 2014 | 79 | 0.030 |
Why?
|
| Overweight | 1 | 2015 | 266 | 0.030 |
Why?
|
| Disease Progression | 1 | 2014 | 259 | 0.030 |
Why?
|
| Biomarkers | 1 | 2014 | 306 | 0.030 |
Why?
|
| Intermittent Pneumatic Compression Devices | 1 | 2012 | 2 | 0.020 |
Why?
|
| Heparin | 1 | 2012 | 9 | 0.020 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2011 | 32 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 114 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 120 | 0.020 |
Why?
|
| Centers for Medicare and Medicaid Services (U.S.) | 1 | 2011 | 4 | 0.020 |
Why?
|
| Monte Carlo Method | 1 | 2011 | 13 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2011 | 10 | 0.020 |
Why?
|
| Contraindications | 1 | 2011 | 14 | 0.020 |
Why?
|
| Neoplasms | 1 | 2016 | 448 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2011 | 24 | 0.020 |
Why?
|
| Cerebrovascular Circulation | 1 | 2010 | 2 | 0.020 |
Why?
|
| National Health Programs | 1 | 2010 | 12 | 0.020 |
Why?
|
| Quality Control | 1 | 2010 | 42 | 0.020 |
Why?
|
| Medicare | 1 | 2011 | 201 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2010 | 74 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2010 | 218 | 0.020 |
Why?
|
| Drug Prescriptions | 1 | 2010 | 148 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2010 | 175 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2010 | 278 | 0.020 |
Why?
|
| Smoking | 1 | 2010 | 428 | 0.020 |
Why?
|
| United Kingdom | 1 | 2007 | 25 | 0.020 |
Why?
|
| Health Planning Guidelines | 1 | 2006 | 8 | 0.020 |
Why?
|
| Review Literature as Topic | 1 | 2006 | 12 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2011 | 707 | 0.020 |
Why?
|
| Logistic Models | 1 | 2007 | 884 | 0.010 |
Why?
|